Financial Data and Key Metrics Changes - For the third quarter of fiscal 2026, revenue increased by 10.2% to $4 million from $3.6 million in the prior year quarter [10] - Gross profit for the quarter totaled $3.2 million, up 17.6% from $2.8 million for the prior year period, with a gross profit percentage improvement to 81.5% from 76.4% [11] - EBITDA for the quarter was $280,000, corresponding to $0.01 on a per-share basis, marking the third consecutive quarter of positive EBITDA [14] Business Line Data and Key Metrics Changes - Recurring revenue reflects strong market adoption of the primary subscription model, driven by the popularity of FDA-cleared cardiac monitor devices, particularly the next-generation Biotres Pro [9] - Technology fees accounted for 91.2% of the quarter's total revenue, indicating strong customer retention and quality of support services [11] - Sales of BioCore Pro, the next-generation cardiac monitoring device, continued to expand, contributing to improved utilization and accelerating the path towards breakeven [7] Market Data and Key Metrics Changes - The digital health app user base grew from 4,500 to over 44,000 in two years, with an expanding network of over 2,500 providers supporting 400,000 patients annually [10] - The focus on atrial fibrillation as a primary contributor to strokes remains significant, with early intervention opportunities improving patient outcomes and potentially delivering healthcare cost savings [10] Company Strategy and Development Direction - The company is focused on transitioning from reactive care to proactive management in chronic care markets, particularly in cardiovascular disease [3][4] - Biotricity aims to expand its geographic footprint and is pursuing regulatory approvals internationally while maintaining a primary focus on U.S. market expansion [5][12] - The strategic initiatives and technological advancements are designed to position Biotricity for sustained growth and profitability in 2026 [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and the expectation of turning net income positive in the current year [18] - The company is excited about the prospects for 2026, anticipating sustained growth in the top line and improvements in operational efficiencies [16][18] Other Important Information - Operating expenses for the third quarter were $2.8 million, a decrease of 4.2% compared to the same period last year [12] - The net loss attributable to common stockholders for the quarter was $1.1 million, an improvement from $1.3 million in the prior year period [15] Q&A Session Summary - There were no questions during the Q&A session, and the conference concluded with management expressing excitement about future prospects [17][19]

REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing ...

Core Insights - Biotricity Inc. reported strong financial performance for Q1 of fiscal 2026, achieving a positive EBITDA for the first time, indicating a shift towards profitability and scalability of its business model [1][4][2] Financial Highlights - Revenue increased by 21% to $3.9 million compared to $3.2 million in Q4 FY24 [4] - Gross margin improved to 80.5% from 73.8% in the same quarter last year, driven by increased recurring technology fee revenue and operational efficiencies [4] - Net loss decreased significantly to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25, marking an 80.6% improvement [4] - Positive EBITDA of $333,337 was reported, an increase of 118.7% compared to the prior year quarter [4] - Recurring Technology Fees rose by 11.8% year-over-year to $3.4 million, also reflecting a 7.9% increase from the previous quarter [4] Operational Highlights - The company has established strategic alliances with three of the top Group Purchasing Organizations (GPOs), providing access to approximately 90% of all hospitals in the U.S. [2][4] - Biotricity is expanding its geographic footprint across 70% of the U.S., with penetration into thousands of physicians and hundreds of centers [4] - The company is working towards achieving regulatory approval in international markets, having already secured approvals in Canada, Saudi Arabia, and Argentina [4] Technological Advancements - The expansion of Biotricity's Cardiac AI Cloud platform is supported by partnerships with industry leaders, utilizing over 2 trillion beats of anonymized data to enhance diagnostic accuracy and clinic profitability [1][4] - The company continues to leverage AI technology and workflow automation to improve operational expenses, margins, and revenues [1]

Core Insights - Biotricity Inc. has reported significant financial improvements for fiscal year 2025, showcasing a transformation driven by technology and operational efficiencies [2][8][9] Financial Performance - FY25 revenue increased by 14.3% year-over-year to $13.8 million, up from $12.1 million in FY24 [9] - Gross margin improved to 76.6% in FY25, compared to 69.3% in FY24, attributed to increased recurring technology fee revenue and operational efficiencies [8][9] - The net loss for FY25 decreased by 20% year-over-year to $11.9 million, or $0.56 per share, down from a net loss of $14.9 million, or $1.66 per share, in FY24 [9] - Positive Adjusted EBITDA of $438,260 was achieved in Q4 FY25, marking the first time in the company's history to reach EBITDA positivity [8][9] Operational Highlights - Recurring Technology Fees rose by 12% year-over-year to $12.6 million, significantly outpacing Device Sales revenue [7] - Operating expenses were reduced by 24.5% year-over-year, contributing to improved financial metrics [8] - The company is on track to achieve EBITDA breakeven and long-term profitability in FY26 [2][8] Strategic Developments - Biotricity has expanded its Cardiac AI Cloud platform through strategic partnerships, enhancing its market reach to approximately 90% of hospitals in the U.S. [4][3] - The company is pursuing FDA clearance for its AI clinical model, which is expected to revolutionize medical diagnostics and chronic care management [3][4] - Collaborative partnerships established during FY25 and FY26 are aimed at capitalizing on new market channels and value-based care programs [4] Market Position - Biotricity is positioned within a total addressable market of $35 billion, focusing on innovative and accessible cardiac care solutions [15] - The company has secured strategic alliances with three of the top Group Purchasing Organizations (GPOs), representing a significant portion of U.S. hospitals [15]